Literature DB >> 9371515

The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct.

Y Lin1, T Nomura, T Yamashita, D Dorjsuren, H Tang, S Murakami.   

Abstract

Transactivation of viral and host genes expression by hepatitis B virus X protein (HBx) is believed to be involved in hepatocarcinogenesis. The interaction of HBx with the tumor suppressor p53 and its inhibitory effect on p53 functions have been reported recently. However, the question of whether p53 is directly involved in HBx transactivation has not yet been addressed. In this study, we delineated the interaction sites of HBx and p53 using far-Western blotting and glutathione S-transferase-resin pull-down assays. The results indicate that the HBx-binding sites are located within the oligomerization and specific DNA-binding domains of p53 and that the p53-binding site was confined to a small region in the HBx transactivation domain. Mutual interference of the transactivations by HBx and p53 was detected by CAT assays in a transient transfection system. Strikingly, transactivation by HBx was observed in the p53-negative cells, Saos-2 and Hep3B, indicating that the transactivation and the p53-inhibiting functions of HBx are mutually interfering but distinct.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371515

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis.

Authors:  X W Wang
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

2.  Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level.

Authors:  Chi-Ming Chiu; Shiou-Hwei Yeh; Pei-Jer Chen; Ti-Jung Kuo; Ching-Ju Chang; Po-Jen Chen; Wan-Jen Yang; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-26       Impact factor: 11.205

3.  Hepatitis B Virus Core Promoter A1762T/G1764A (TA)/T1753A/T1768A Mutations Contribute to Hepatocarcinogenesis by Deregulating Skp2 and P53.

Authors:  Jian Yan; Zhicheng Yao; Kunpeng Hu; Yuesi Zhong; Mingliang Li; Zhiyong Xiong; Meihai Deng
Journal:  Dig Dis Sci       Date:  2015-01-08       Impact factor: 3.199

Review 4.  Chronic hepatitis B in hepatocarcinogenesis.

Authors:  N H Park; I H Song; Y-H Chung
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

5.  Molecular Pathogenesis of Hepatitis-B-virus-associated Hepatocellular Carcinoma.

Authors:  Neung Hwa Park; Il Han Song; Young-Hwa Chung
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

6.  Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21.

Authors:  Yuehua Huang; Shuping Tong; Andrew W Tai; Munira Hussain; Anna S F Lok
Journal:  Gastroenterology       Date:  2011-06-24       Impact factor: 22.682

7.  Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein.

Authors:  Cheryl Chan; Yu Wang; Pierce K H Chow; Alexander Y F Chung; London L P J Ooi; Caroline G Lee
Journal:  Mol Cell Biol       Date:  2012-11-12       Impact factor: 4.272

Review 8.  Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma.

Authors:  Ashraf Ali; Hany Abdel-Hafiz; Mohd Suhail; Amany Al-Mars; Mohammad Khalid Zakaria; Kaneez Fatima; Sultan Ahmad; Esam Azhar; Adeel Chaudhary; Ishtiaq Qadri
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

9.  Natural variants of hepatitis B virus X protein have differential effects on the expression of cyclin-dependent kinase inhibitor p21 gene.

Authors:  Hyun Jin Kwun; Kyung Lib Jang
Journal:  Nucleic Acids Res       Date:  2004-04-23       Impact factor: 16.971

Review 10.  Hepatitis B Virus X and Regulation of Viral Gene Expression.

Authors:  Betty L Slagle; Michael J Bouchard
Journal:  Cold Spring Harb Perspect Med       Date:  2016-01-08       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.